Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3052174 | 1.00 | BRAF (0.63) | BRAFRAF1 | |
| SCHEMBL3052167 | 1.00 | BRAF (0.63) | BRAFRAF1 | |
| SCHEMBL3051056 | 0.89 | BRAF (0.59) | BRAFRAF1 | |
| SCHEMBL3051066 | 0.89 | BRAF (0.59) | BRAFRAF1 | |
| SCHEMBL3056949 | 0.89 | BRAF (0.59) | BRAFRAF1 | |
| SCHEMBL3054496 | 0.87 | BRAF (0.66) | BRAFRAF1 | |
| SCHEMBL3059302 | 0.86 | BRAF (0.55) | BRAFRAF1 | |
| SCHEMBL3059304 | 0.86 | BRAF (0.55) | BRAFRAF1 | |
| SCHEMBL3063346 | 0.86 | BRAF (0.55) | BRAFRAF1 | |
| SCHEMBL3064945 | 0.86 | BRAF (0.67) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | claimed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| WO-2009050228-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | BRAF 227/4885RAF1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.